Original Article

You have full text access to this OnlineOpen article

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

  1. David L Kendler1,*,
  2. Christian Roux2,
  3. Claude Laurent Benhamou3,
  4. Jacques P Brown4,
  5. Michael Lillestol5,
  6. Suresh Siddhanti6,
  7. Hoi-Shen Man6,
  8. Javier San Martin6,
  9. Henry G Bone7

Article first published online: 14 DEC 2009

DOI: 10.1359/jbmr.090716

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 1, pages 72–81, January 2010

Additional Information

How to Cite

Kendler, D. L., Roux, C., Benhamou, C. L., Brown, J. P., Lillestol, M., Siddhanti, S., Man, H.-S., Martin, J. S. and Bone, H. G. (2010), Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res, 25: 72–81. doi: 10.1359/jbmr.090716

Author Information

  1. 1

    Clinical Research Centre, Vancouver, British Columbia, Canada

  2. 2

    Paris Descartes University Hôpital Cochin, Paris, France

  3. 3

    INSERM Unit U 658, Orleans, France

  4. 4

    CHUQ, Laval University, Quebec City, Quebec, Canada

  5. 5

    Internal Medicine Associates, Fargo, ND, USA

  6. 6

    Amgen Inc., Thousand Oaks, CA, USA

  7. 7

    Michigan Bone and Mineral Clinic, Detroit, MI, USA

*600-1285 W Broadway, Vancouver, British Columbia, V6H 3X8 Canada.

Publication History

  1. Issue published online: 20 JAN 2010
  2. Article first published online: 14 DEC 2009
  3. Manuscript Accepted: 6 JUL 2009
  4. Manuscript Revised: 22 MAY 2009
  5. Manuscript Received: 31 DEC 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (146K)

References

  • 1
    Anonymous. Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int. 1997; 7: 1–6.
  • 2
    Bone Health and Osteoporosis: A Report of the Surgeon General. US Department of Health and Human Services, Washington DC, 2004.
  • 3
    NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285: 785–795.
  • 4
    Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17: 1726–1733.
  • 5
    Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999; 145: 527–538.
  • 6
    Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000; 157: 435–448.
  • 7
    Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93: 165–176.
  • 8
    Udagawa N, Takahashi N, Yasuda H, et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology. 2000; 141: 3478–3484.
  • 9
    Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998; 95: 3597–3602.
  • 10
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, Martin JS. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008; 93: 2149–2157.
  • 11
    Lewiecki EM, Miller PD, McClung MR, et al. for the AMG 162 Bone Loss Study Group. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007; 22: 1832–1841.
    Direct Link:
  • 12
    McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006; 354: 821–831.
  • 13
    Miller PD, Bolognese MA, Lewiecki EM, et al., for the AMG 162 Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008; 43: 222–229.
  • 14
    Cummings SR, McClung MR, Christiansen C, et al. The effects of denosumab on fracture risk in women with osteoporosis. Osteoporos Int. 2009; 20: 167.
  • 15
    Top 200 brand drugs by units in 2007. Drug Topics 2008.
  • 16
    Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006; 17: 1645–1652.
  • 17
    Russell RG, Watts NB, Ebetino E, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19: 733–759.
  • 18
    Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009; 24: 153–161.
    Direct Link:
  • 19
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31–41.
  • 20
    The International Society for Clinical Densitometry 2006 ISCD Understanding Bone Densitometry. http://www.iscd.org/visitors/pdfs/UnderstandingBMDTesting2006-Final.ppt. Accessed December 10, 2009.
  • 21
    Stock JL, Bell NH, Chesnut CH 3rd, et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med. 1997; 103: 291–297.
  • 22
    Bone HG, Hosking D, Devogelaer J, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350: 1189–1199.
  • 23
    McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007; 41: 122–128.
  • 24
    Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res. 2007; 86: 1022–1033.
  • 25
    Silverman SL, Gold DT. Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep. 2008; 10: 118–122.
  • 26
    Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005; 165: 2414–2419.
  • 27
    Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004; 15: 1003–1008.
  • 28
    Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006; 38: 922–928.
  • 29
    Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81: 1013–1022.
  • 30
    Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int. 2007; 18: 271–277.
  • 31
    Delmas PD, Calvo G, Boers M, et al. The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int. 2002; 13: 1–5.
  • 32
    Kanis JA, Alexandre JM, Bone HG, et al. Study design in osteoporosis: a European perspective. J Bone Miner Res. 2003; 18: 1133–1138.
    Direct Link:
  • 33
    Bouxsein ML, Delmas PD. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res. 2008; 23: 1155–1167.
    Direct Link:
  • 34
    Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21: 1785–1790.
    Direct Link:
  • 35
    Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002; 87: 1586–1592.
  • 36
    Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum. 1999; 42: 1246–1254.
    Direct Link:
  • 37
    Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002; 17: 1–10.
    Direct Link:
  • 38
    University of Sheffield Bone Marker Laboratory; available at www.shef.ac.uk/medicine/research/sections/musculoskeletal/bonemarkerlab/methodologies.html. Accessed March 3, 2009.
View Full Article (HTML) Get PDF (146K)